The desk / continuation
Dispatches 181–191 of 476; page 16 of 40.
An exhaustive 2000+ word educational guide to Codeine Phosphate in the Indian context. Covers 24+ brand names with prices from 1mg, Jan Aushadhi status, CYP2D6 metabolism, lethal doses, NDPS Act regulations, and harm-reduction resources. Data as of May 2026.
Health & MedicineA clinical and harm-reduction guide to Clonazepam in India, exploring its role in seizure management, its use in REM sleep disorders, Jan Aushadhi pricing, and the severe risks of physical dependence as of 2026.
GeneralA comprehensive clinical and harm-reduction guide to Lorazepam (Ativan) in India, exploring its unique liver-safe metabolic pathway, its role in treating status epilepticus, Jan Aushadhi pricing, and current misuse trends as of 2026.
GeneralAn exhaustive clinical and harm-reduction guide to Nitrazepam in India, exploring its potent hypnotic effects, its role in treating infantile spasms, Jan Aushadhi pricing, and its history as a potential date-rape drug as of 2026.
GeneralA comprehensive clinical and harm-reduction guide to Midazolam in India, exploring its role in procedural sedation, the life-saving potential of nasal sprays in pediatric seizures, Jan Aushadhi pricing, and safety protocols as of 2026.
GeneralA comprehensive clinical and harm-reduction guide to Chlordiazepoxide (Librium) in India, exploring its history as the first benzo, its vital role in alcohol detox, Jan Aushadhi pricing, and its combination use for IBS as of 2026.
GeneralA comprehensive clinical and harm-reduction guide to Clobazam in India, exploring its unique 1,5-benzodiazepine structure, its role in treating difficult epilepsies, Jan Aushadhi pricing, and the intermittent dosing protocols for catamenial epilepsy as of 2026.
GeneralA comprehensive clinical and harm-reduction guide to Zolpidem (Zolfresh) in India, exploring its selective GABA-A action, the risk of complex sleep behaviors, Jan Aushadhi pricing, and its paradoxical effect on brain injuries as of 2026.
GeneralA comprehensive clinical and harm-reduction guide to Zopiclone in India, exploring its cyclopyrrolone pharmacology, the hallmark 'metallic taste,' Jan Aushadhi unavailability, and its April 2026 shift to Schedule H1.
GeneralA comprehensive clinical and harm-reduction guide to Eszopiclone in India, exploring its (S)-enantiomer advantage, its role in chronic insomnia management, market pricing, and the strict 2026 Schedule H1 regulations.
GeneralA comprehensive clinical and harm-reduction guide to Phenobarbital in India, exploring its role as an essential antiepileptic, Jan Aushadhi pricing, the dangers of barbiturate withdrawal, and its extreme 100-hour half-life as of 2026.
GeneralA comprehensive clinical and harm-reduction guide to Tramadol Hydrochloride in the Indian context, covering pharmacology, NDPS regulations, and market pricing as of 2026.
General